Global Juvenile Macular Degeneration (Stargardt Disease) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Diagnosis;

Fluroscein Angiography (FA), Fundus Autofluorescence (FAF), Optical Coherence Tomography (OCT), and Electroretinography.

By Devices;

Magnifying Spectacles, Magnifiers, and Reading Telescopes.

By End User;

Hospitals & Eye Clinics, and Research & Academic Institutes.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn398309158 Published Date: April, 2025 Updated Date: May, 2025

Introduction

Global Juvenile Macular Degeneration (Stargardt Disease) Market (USD Million), 2021 - 2031

In the year 2024, the Global Juvenile Macular Degeneration (Stargardt Disease) Market was valued at USD 1,312.08 million. The size of this market is expected to increase to USD 2,065.91 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.7%.


Global Juvenile Macular Degeneration (Stargardt Disease) Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 6.7 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.7 %
Market Size (2024)USD 1,312.08 Million
Market Size (2031)USD 2,065.91 Million
Market ConcentrationMedium
Report Pages370
1,312.08
2024
2,065.91
2031

Major Players

  • Genentech, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Allergan plc
  • Sanofi Genzyme
  • ProQR Therapeutics
  • Astellas Pharma Inc.
  • Spark Therapeutics
  • Editas Medicine
  • MeiraGTx Holdings plc

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Juvenile Macular Degeneration (Stargardt Disease) Market

Fragmented - Highly competitive market without dominant players


The Global Juvenile Macular Degeneration (Stargardt Disease) Market is witnessing gradual growth, driven by a rising number of confirmed cases. Stargardt disease, recognized as the most prevalent inherited macular condition affecting children and adolescents, results in progressive central vision loss. It currently accounts for nearly 25% of all juvenile retinal dystrophies, underscoring its clinical relevance and increasing demand for early intervention and long-term care solutions.

A surge in awareness campaigns and access to advanced screening methods has significantly improved early diagnosis rates. The adoption of optical coherence tomography (OCT) and genetic testing has led to a 40% rise in patient screenings in recent years. This heightened diagnostic activity is enabling more individuals to receive timely treatment and monitoring, which is essential for managing disease progression effectively.

Technological Advancements in Genetic Therapies
Cutting-edge developments in gene therapy and cell-based treatments are transforming the treatment landscape. Innovations targeting mutations in the ABCA4 gene, responsible for over 80% of Stargardt cases, are at the forefront of clinical research. Stem cell approaches and retinal regeneration techniques now represent almost 35% of research investments in the segment, offering hope for more durable and targeted interventions in the near future.

Supportive Regulatory and Research Framework
Government and institutional support continues to fuel research and innovation in rare eye disorders. Currently, around 30% of rare disease funding is allocated to ocular conditions, with Stargardt disease gaining increased attention. Public-private partnerships and global research collaborations are fostering advancements in drug development and accelerating the clinical pipeline.

Market Outlook and Long-Term Growth Potential
The juvenile macular degeneration market is set for consistent expansion, bolstered by ongoing innovation and unmet clinical needs. The past decade has seen a 50% increase in clinical research activity focused on Stargardt disease, reflecting industry commitment to finding lasting therapeutic solutions. As diagnostic capabilities advance and investment continues, the market is positioned to deliver meaningful breakthroughs for patients worldwide

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Diagnosis
    2. Market Snapshot, By Devices
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Global Juvenile Macular Degeneration (Stargardt Disease) Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Genetic Research
        2. Increasing Awareness
        3. Regulatory Support
      2. Restraints
        1. Limited Treatment Options
        2. High Treatment Costs
        3. Lack of Healthcare Access
        4. Genetic Complexity
      3. Opportunities
        1. Novel Therapeutic Approaches
        2. Collaborative Research Efforts
        3. Patient Advocacy Engagement
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Juvenile Macular Degeneration (Stargardt Disease) Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Fluroscein Angiography (FA)
      2. Fundus Autofluorescence (FAF)
      3. Optical Coherence Tomography (OCT)
      4. Electroretinography
    2. Global Juvenile Macular Degeneration (Stargardt Disease) Market, By Devices, 2021 - 2031 (USD Million)
      1. Magnifying Spectacles
      2. Magnifiers
      3. Reading Telescopes
    3. Global Juvenile Macular Degeneration (Stargardt Disease) Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals & Eye Clinics
      2. Research & Academic Institutes
    4. Global Juvenile Macular Degeneration (Stargardt Disease) Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Genentech, Inc.
      2. Novartis AG
      3. Regeneron Pharmaceuticals, Inc.
      4. Allergan plc
      5. Sanofi Genzyme
      6. ProQR Therapeutics
      7. Astellas Pharma Inc.
      8. Spark Therapeutics
      9. Editas Medicine
      10. MeiraGTx Holdings plc
  7. Analyst Views
  8. Future Outlook of the Market